PURPOSE: A dramatic improvement in the survival of patients with chronic myeloid leukemia (CML) occurred after the introduction of imatinib mesylate, the first tyrosine kinase inhibitor (TKI). We assessed how these changes affected the life expectancy of patients with CML and life-years lost as a...
Imatinib may give normal life expectancy to patients with CML.(just in)(chronic myelogenous leukemia)(Report)McBride, Deborah
who is eagerly anticipating the birth and early years of a grandchild or the fulfillment of an important lifetime accomplishment might be willing to com- promise on overall life expectancy to avoid a 20- 41% risk of death within the next year.Similar, though less stark, tradeoffs apply to ...
We report a randomized prospective phase 3 study (CLL7), designed to evaluate the efficacy of fludarabine, cyclophosphamide, and rituximab (FCR) in patients with an early-stage high-risk chronic lymphocytic leukemia (CLL). Eight hundred patients with untreated-stage Binet A disease were enrolled ...
From the laboratory perspective, effective management of patients with chronic myeloid leukemia (CML) requires accurate diagnosis, assessment of prognostic markers, sequential assessment of levels of residual disease and investigation of possible reasons
There has been a lack of meta-analyses and systematic reviews conducted in chronic lymphocytic leukemia (CLL). Structured searches were conducted in publication and conference databases to identify randomized controlled trials (RCTs) that are reporting efficacy data for treatment-naïve CLL ...
The anti-CD52 monoclonal antibody alemtuzumab is highly active in the treatment of chronic lymphocytic leukemia (CLL) in patients with previously treated, ... SM O'Brien,MJ Keating,ES Mocarski - 《Clinical Lymphoma & Myeloma》 被引量: 140发表: 2006年 Successful treatment of refractory pure red...
No. 136: Establishment of a pre-clinical in vivo platform spanning low-risk to high-risk CLL Chronic lymphocytic leukemia is extraordinarily heterogeneous in its clinical course. While some patients survive for decades without the need for therapeutic intervention, others suffer from rapidly progressing...
Patients must also have an ECOG performance status of 0 to 2 and a life expectancy of 12 weeks or more. REFERENCES: 1. Terns Pharmaceuticals announces orphan drug designation granted to TERN-701 for the treatment of chronic myeloid leukemia. News release. Terns Pharmaceuticals, Inc. March 11,...
Chemotherapy for CLL consisted ... JV Teichmann,G Sieber,WD Ludwig,... - 《Leukemia Research》 被引量: 36发表: 1986年 Cytostatic Therapy of Chronic Myelogenous Leukemia: Review and Perspectives There is general agreement that life expectancy of patients with chronic myelogenous leukemia (CML) has...